cemiplimab
cemiplimab: 93 clinical trials tracked.
cemiplimab evidence translation
What we can confirm
93 tracked trials
What it means
What to watch
Prepared research question
What is verified about cemiplimab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 7 study sponsors
Related indications
Clinical Trial Registry Records (93)showing 10 most recent
Phase II Trial of Perioperative Cemiplimab in Patients With Resectable Non-small Cell Lung Cancer and PD-L1 ≥50%
Primary endpoint: Pathologic Complete Response Rate
A Phase 2 Single-arm Study of Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement or Other High Risk Features
Primary endpoint: Pathologic complete response (pCR) rate
RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer
Primary endpoint: Recurrence free survival (RFS) as per RECIST 1.1
Phase 2 Platform Trial of Combination Therapies for Participants With Locally Advanced Basal Cell Carcinoma: Master Protocol With Cemiplimab Monotherapy as Comparator Arm
Primary endpoint: Objective Response Rate (ORR) by blinded independent central review (BICR) per Composite Response Criteria
A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)
Primary endpoint: Overall response rate (ORR)
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial
Primary endpoint: Major pathologic response (MPR)
A Pilot Randomized Trial of Induction Cemiplimab With or Without Fianlimab in De-escalated Chemoradiation for Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma
Primary endpoint: Complete response rate
Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)
Primary endpoint: Rate of pathologic downstaging
A Randomized Phase II Study of the Efficacy of Laser Interstitial Thermal Therapy (LiTT) Combined With Cemiplimab Versus Physician's Choice Chemotherapy in Recurrent Glioblastomas
Primary endpoint: Progression-free survival (PFS) at Month 6 (PFS6)
A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer
Primary endpoint: Progression free survival (PFS)